Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer
- 30 December 2008
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 69 (4), 419-427
- https://doi.org/10.1002/pros.20908
Abstract
BACKGROUND Prostate specific antigen (PSA) is widely used for prostate cancer screening but its levels are influenced by many non cancer‐related factors. The goal of the study is to estimate the effect of genetic variants on PSA levels. METHODS We evaluated the association of SNPs that were reported to be associated with prostate cancer risk in recent genome‐wide association studies with plasma PSA levels in a Swedish study population, including 1,722 control subjects without a diagnosis of prostate cancer. RESULTS Of the 16 SNPs analyzed in control subjects, significant associations with PSA levels (P ≤ 0.05) were found for six SNPs. These six SNPs had a cumulative effect on PSA levels; the mean PSA levels in men were almost twofold increased across increasing quintile of number of PSA associated alleles, P‐trend = 3.4 × 10−14. In this Swedish study population risk allele frequencies were similar among T1c case patients (cancer detected by elevated PSA levels alone) as compared to T2 and above prostate cancer case patients. CONCLUSIONS Results from this study may have two important clinical implications. The cumulative effect of six SNPs on PSA levels suggests genetic‐specific PSA cutoff values may be used to improve the discriminatory performance of this test for prostate cancer; and the dual associations of these SNPs with PSA levels and prostate cancer risk raise a concern that some of reported prostate cancer risk‐associated SNPs may be confounded by the prevalent use of PSA screening. Prostate 69:419–427, 2009.Keywords
This publication has 36 references indexed in Scilit:
- Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSAInternational Journal of Andrology, 2009
- Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the DiseaseClinical Cancer Research, 2008
- Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control studyBMC Medicine, 2008
- Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancerNature Genetics, 2008
- Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 YearsJournal of Clinical Oncology, 2007
- PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibilityCarcinogenesis: Integrative Cancer Research, 2006
- Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSACancer Epidemiology, Biomarkers & Prevention, 2006
- A common variant associated with prostate cancer in European and African populationsNature Genetics, 2006
- Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American menProstate Cancer and Prostatic Diseases, 2005
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987